Scientific Program

Sunday 1 December, 2013

09:30 – 19:30	Registration desk open		
10:00 – 12:00	Room: Bourke room 3		Room: Bourke room 2
	PGx: new research interests and directions		**ASCEPT Council Meeting**
	Chair: Prof Andrew Somogyi		
	Inter individual variation in the expression of pharmacogenes is epigenetic control important? Dr Nuala Helsby, School of Medical Sciences, The University of Auckland, NZ		
	"NHMRC Best of 10" Fluoropyrimidine toxicity: A nasty way to die. But can pharmacogenetics help? Dr John Duley, School of Pharmacy, The University of Queensland		
	Short presentation TBC		
	Short presentation TBC		
	SIG meeting		
14:30 – 16:30	Room: Level 17	Room: Bourke room 2	Room: Bourke room 3
	Careers workshop Careers spanning academia, industry and government	**Clinical Pharmacology workshop** Pharmacokinetic models - uses and misuses	**Education Forum workshop** Ideas Exchange: Engaging the Net generation
	Chairs: Ms Michelle Bullen, PhD student, Monash University; Mr Adrian Campbell, PhD student, University of New South Wales **Convenor**: Dr Barbara Kemp-Harper, Monash University	**Chair**: Assoc Prof Matt Doogue	**Chair**: Dr Elizabeth Davis Sponsored by MONASH University
	When I grow up, I want to be.... Dr Shane Patella, Director Pantheon Consulting	**A century of lessons in and from pharmacokinetics** Prof Evan Begg, University of Otago	**Using videos in practical teaching** Dr Elizabeth Davis, Monash University
	A new career in the Pharmaceutical Industry Ms Chantelle Gardiner-Mann, Medical Information and Pharmacovigilance Associate, UCB	**Using population pharmacokinetics, what I've learnt so far** Dr Dan Wright, School of Pharmacy, University of Otago	**An iPad/iPhone pharmacology resource** Assoc Prof Lynette Fernandes, University of Western Australia
	Opportunities stemming from postgraduate research: Where do I fit in? Dr Vidya Perera, Postdoctoral Fellow, Novartis; University of Buffalo, USA	**Pharmacokinetic analyses and clinical studies** Prof Carl Kirkpatrick, Monash University	**Using a TBL approach and the 4 S's to engage 1st yr B.Nursing students in the learning of pharmacodynamics** Dr Janet Coller, University of Adelaide
	Transitioning Careers- How did I wind up here? A journey from Researcher to Government Scientist & Policy Advisor to S&T Policy Think Tank Dr Margaret Hartley, CEO, Australian Academy of Technological Sciences and Engineering	**Panel Discussion**	**Using Mahara / EPortfolio for engaging students in group work** Dr Nicole Jones, University of New South Wales
			SIG meeting
17:00 – 18:00	Room: Level 17		
	Opening session and plenary presentation		
	Chair: Prof David Le Couteur, ASCEPT President		
	We are all in this together! Paths to better collaboration for drug discovery and development - 102 Dr Patrick Smith, Chief Scientific Officer, d3 Medicine LLC and Dr Craig Rayner, CEO, d3 Medicine LLC		
18:00 – 19:30	Level 17		
	Welcome Reception		



Monday 2 December, 2013

07:00 – 18:00 Registration desk open

07:30 – 08:30

Room: The Pavillion

Poster presentations: Cardiovascular; Clinical Pharmacology; Drug Discovery; Drug Disposition and Response

Sponsored by PHARMACOLOGY & THERAPEUTICS — THE UNIVERSITY OF MELBOURNE

Room: Bayside room 5 & 6

SIG meeting: Neuro- and Behavioural Pharmacology

Room: Bourke room 1 & 2

SIG meeting: Toxicology

08:30 – 09:30

Room: Level 17

Plenary presentation: ASCEPT Michael Rand lecture

Sponsored by cera — CENTRE FOR EDUCATION & RESEARCH ON AGEING

Chair: Prof David Le Couteur, ASCEPT President

Reciprocal relationships: The role of 'topography' in drug discovery
Prof Arthur Christopoulos, Professor of Pharmacology, Monash University

09:30 – 10:00 Level 2 foyer

Morning tea with exhibitors

10:00 – 12:00

Room: Level 17

Symposium 1:
The long and winding road to discovering drugs for brain and mind disorders

Chairs: Dr Nicole Jones
Dr Angela Finch

Alzheimer's disease and Parkinson's disease: the search for a cure - 103
Prof Ashley Bush, Florey Institute of Neuroscience and Mental Health, The University of Melbourne

Neuropeptides and reward-seeking - 104
Prof Andrew Lawrence, Florey Institute of Neuroscience and Mental Health, The University of Melbourne

Targeting the P2X7R in the search for new antidepressants - 105
Prof Michael Kassiou, Brain and Mind Research Institute, The University of Sydney

Nove WITHDRAWN **xiety - 106**
Dr De[illegible]

Room: Bayside room 5 & 6

Symposium 2:
Barriers to pharmacogenomic testing being incorporated into clinical practice

Chairs: Dr Janet Coller
Prof Andrew Somogyi

Translating Pharmacogenomic findings to the Clinic: Challenges and Opportunities - 107
Dr Justin Rubio, GlaxoSmithKline, UK

Role of basic science and impact of population ethnicity on application of tests - 108
Prof Michael Murray, The University of Sydney

The challenges of making reimbursement decisions about personalised medicine - 109
Prof Robyn Ward, University of New South Wales

Pharmacogenomic testing for Australia: your way or our way or Highway 62: revisited - 110
Prof Andrew Somogyi, University of Adelaide

Room: Bourke room 1 & 2

Oral presentations 1:
Urogenital/Gastrointestinal/Respiratory/ Inflammation

Chairs: Dr Donna Sellers
Prof Alastair Stewart

The effect of sildenafil on spontaneous contractions in human prostate tissue - 111
Brad Wittmer, Department of Anatomy and Developmental Biology, Monash University, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences

An aqueous-soluble polar bioactive is responsible for the inhibitory effect of stinging nettle leaf extract on the purinergic component of contractility in the rat prostate gland - 112
Nicole Eise, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences

The effect of Botulinum toxin type A on release of substance P, ATP and acetylcholine in porcine bladder - 113
Forough Bahadory, School of Medical Sciences, University of New South Wales

Potential role for pannexin-2 in the enteric nervous system of the human colon - 114
Erica Diezmos, Dept of Pharmacology, School of Medical Sciences, University of New South Wales

Establishing a refined model of the contribution of airway epithelial damage and fibrosis to the pathogenesis of asthma - 115
Krupesh Patel, Fibrosis Laboratory, Department of Pharmacology, Monash University

Evidence for endosomal reactive oxygen species production in endothelial cells in response to influenza A virus infection - 116
Keshia Hendricks, Monash University

Sub-chronic smoking alters calcium signalling to increase small airway contraction in mice - 117
Chantal Donovan, Lung Health Research Centre, Department of Pharmacology and Therapeutics, The University of Melbourne

Extracellular annexin A2 mediates inflammation and fibro-proliferation in models of pulmonary fibrosis - 118
Michael Schuliga, The University of Melbourne

12:00 – 13:30	Level 2 foyer	Room: The Pavillion	Room: Bourke room 1 & 2
	Lunch with exhibitors	**Poster presentations: Cardiovascular; Clinical Pharmacology; Drug Discovery; Drug Disposition and Response**	**SIG meeting: Urogenital and Gastrointestinal**
13:30 – 15:30	Room: Level 17	Room: Bayside room 5 & 6	Room: Bourke room 1 & 2
	Oral presentations 2: Drug Discovery 1	**Oral presentations 3: Neurobehavioural/Toxicology**	**Oral presentations 4: Clinical Trainee/Education**
	Chair: Prof Greg Monteith	**Chairs**: Dr Ian Musgrave Dr Nicole Jones	**Chairs**: Assoc Prof Matt Doogue Dr Elizabeth Davis
	Bitopic modulators of the α_{1A} adrenoceptor - 119 Angela Finch, Department of Pharmacology, School of Medical Sciences, University of New South Wales	**Enhancing the blood-brain barrier efflux of ß-amyloid: a novel approach for the treatment of Alzheimer's disease? - 127** Joseph Nicolazzo, Drug Delivery, Disposition and Dynamics, Monash University	**Bioequivalence of generic mycophenolate mofetil in paediatric renal transplantation - 135** David Metz, Royal Children's Hospital
	Pathway-selective modulation of CB1 receptor signalling by the allosteric modulator Org27569 - 120 Elham Khajehali, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences	**A combined Mutational Study with Various Antagonists on Serine Residue within the Orthosteric Binding Pocket of ρ1 GABAC Ion Channel Receptors: A Structure-Based Study - 128** Moawiah Naffaa, The University of Sydney	**The pharmacokinetics of thiamine in alcohol dependent people: Protocol - 136** Jonathan Brett, Drug Health
	TRPV4 and Shear Stress Mechanotransduction in Endothelial Cell - 121 Sara Baratchi, Health Innovations Research Institute, School of Electrical and Computer Engineering, RMIT University	**Expression of the small interacting protein CRIP1a modulates cannabinoid CB1 receptor mediated signalling - 129** Nilushi Karunaratne, Monash Institute of Pharmaceutical Sciences	**The effect of a Bayesian method of gentamicin monito WITHDRAWN nd cost: comparison to existing dosing strategies - 137** Mitchell McKean, Clinical Pharmacology, Royal Brisbane and Women's Hospital
	Molecular Determinants of Allosteric Ligand Binding and Modulation at the M1 Muscarinic Acetylcholine Receptor - 122 Alaa Abdul-Ridha, Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology	**Contribution of beta1 adrenoceptors to the development of alcohol dependence - 130** Paul Klenowski, Translational Research Institute, Queensland University of Technology	**Outcomes of sedation for acute behavioural disturbance in St Vincent's Hospital Emergency Department - 138** Catherine Lucas, Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital; The University of New South Wales
	Delineating the dynamics of mu-opioid receptor signalling and regulation - 123 Meritxell Canals, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences	***In vivo* human dermal nanoparticle toxicology - myth or reality? - 131** Michael Roberts, School of Pharmacy and Medical Sciences, University of South Australia, School of Medicine, The University of Queensland	**Pilot study of a drug minimisation guide applied to older patients in hospital - 139** Andrew Finch, Clinical Pharmacology, Princess Alexandra Hospital
	Antiproliferative actions of novel w-3 epoxyfatty acids and isosteric analogues in human breast cancer cells - 124 Michael Murray, Discipline of Pharmacology, The University of Sydney	**Accumulation of nanoparticles in the mononuclear phagocyte system: role of albumin binding and unfolding on the surface of nanoparticles - 132** Gysell Mortimer, School of Biomedical Sciences, The University of Queensland	**Development of a 'design your own experiment' practical class to enhance independent research skills in third year neuropharmacology students - 140** Nicole Jones, Department of Pharmacology, University of New South Wales
	Development and Validation of an LC-MS/MS Bioanalytical Method for Quantification of Pyridoxal 5´-Phosphate (PLP) in Samples of Human Whole Blood - 125 Sussan Ghassabian, Centre for Integrated Preclinical Drug Development, The University of Queensland	**Uptake and toxicity of nanoparticles used in medicine varies with particle size and protein binding - 133** Nicolin Tirtaatmadja, School of Biomedical Science, The University of Queensland	**Medicines education for Junior Medical Officers (JMOs) during hospital orientation - 141** Alexandra Bennett, NSW Therapeutic Advisory Group
	Identifying origins of affinity, selectivity and allosterism on the α_1 adrenoceptors - 126 Adrian Campbell, School of Medical Sciences, University of New South Wales	**Macronutrient related hepatotoxic changes provide a link between caloric restriction and inflamm-ageing - 134** Rahul Gokarn, Biogerontology Group, Sydney Medical School; ANZAC Research Institute; Centre for Education and Research on Ageing; Charles Perkins Centre	**Learning activities to increase student engagement with the results presented in journal articles - 142** Angela Finch, Department of Pharmacology, School of Medical Sciences, University of New South Wales
15:30 – 16:00	Level 2 foyer		
	Afternoon tea with exhibitors		



16:00 – 18:00	Room: Bourke room 1 & 2	Room: Bayside room 5 & 6	Room: Level 17
	Oral presentations 5: Drug Disposition and Response	**Oral presentations 6: Cardiovascular 1**	**ASCEPT Denis Wade Johnson & Johnson New Investigators**
	Chair: Prof John Miners	**Chairs**: Prof Robert Widdop Dr Tracey Gaspari	**Chair**: Dr Barbara Kemp-Harper
	Regulation of UDP glucuronosyltransferases 2B15 and 2B17 by microRNAs in cancer cell lines - 143 Dhilushi Wijayakumara, Department of Clinical Pharmacology, Flinders University	**Acute tocomin treatment improves endothelium-dependent relaxation in aortae from diabetic and western diet fed rats - 151** Saher Ali, RMIT University	**Pharmacokinetic/pharmacodynamic strategies to optimise patient therapy - 159** Dr Cornelia Landersdorfer, Monash University
	Induction of sulfotransferase 1A3 by dopamine and its role in neuro-protection from dopamine toxicity - role of D1 receptor-NMDA receptor coupling - 144 Rod Minchin, School of Biomedical Sciences, The University of Queensland	**Evidence for a role of NOX5 in macrophage pathobiology - 152** David Firth, Monash University	**Engineering detergent-stable G protein-coupled receptors enables biophysical profiling of ligand binding and conformational dynamics - 160** Dr Daniel Scott, Howard Florey Institute
	PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulation of cellular trafficking and protein stability - 145 Fanfan Zhou, Faculty of Pharmacy, The University of Sydney	**Attenuation of BNP effects on neutrophil superoxide release in heart failure patients - 153** Saifei Liu, The University of Adelaide	**Novel roles for magnesium channels in cardiovascular disease and development - 161** Dr Tamara Paravicini, The University of Queensland
	Casein kinase 2 is a novel regulator of the human organic anion transporting polypeptide 1A2 (OATP1A2) - 146 Florence Cheung, Faculty of Pharmacy, The University of Sydney	**Evidence for Reciprocal Dysregulation of Asymmetric Dimethylarginine and Myeloperoxidase in Atrial Fibrillation - 154** Nathan Procter, University of Adelaide, The Basil Hetzel Institute	**Interventions to improve healthspan and lifespan in mice - 162** Dr Sarah Mitchell, NIH, USA
	Effect of garlic and gingko on fexofenadine; mechanistic explanation in rats - 147 Robert Milne, School of Pharmacy and Medical Science, University of South Australia	**Omega-3 fatty acid supplementation increases plasma resolvin D1 levels, and decreases aortic dissection, in an apoE-/- mouse model of abdominal aortic dissection - 155** Fraser Russell, Inflammation and Healing Research Cluster, University of the Sunshine Coast	
	Lipid conjugation for drug targeting - 148 Quynh Mai, Monash Institute of Pharmaceutical Science	**Distinct roles for the two human platelet thrombin receptors, PAR1 and PAR4, in thrombus formation - 156** Tejminder Sidhu, Australian Centre for Blood Diseases, Monash University	
	Liver endothelial cell defenestration impairs insulin and glucose uptake in rats - 149 Victoria Cogger, Centre for Education and Research on Ageing and ANZAC Medical Research Institute	**Pharmacological inhibition or genetic deletion of the AT4 Receptor/IRAP provides protection against Ang II-mediated cardiac hypertrophy and cardiac fibrosis - 157** Huey Wen Lee, Department of Pharmacology, Monash University	
	Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing - 150 Michael Dolton, Faculty of Pharmacy, The University of Sydney; Centre for Education and Research on Ageing, Concord Repatriation General Hospital	**The epidermal growth factor receptor ErbB4 mediates neuregulin-induced, but not angiotensin II-induced, cardiomyocyte hypertrophy - 158** Zhen Wang, The University of Queensland	
18:00 – 19:00	Level 2 foyer		
	ASCEPT President's Function (by invitation only)		

Tuesday 3 December, 2013

07:30 – 17:30	Registration desk open		
08:00 – 09:00	Room: The Pavillion		
	Poster presentations: Inflammation/Respiratory; Neuro- and Behavioural Pharmacology; Pharmacogenomics; Toxicology; Urogenital and Gastrointestinal; Education		
09:00 – 10:00	Room: Level 17		
	Plenary presentation - British Pharmacological Society Visitor		
	Chairs: Prof David Le Couteur		
	Drug discovery: lessons from evolution - 201 Dr John Warren, Clinical Scientist, Medicines Assessment Ltd		
10:00 – 10:30	Level 2 foyer		
	Morning tea with exhibitors		
10:30 – 12:30	Room: Bourke room 1 & 2	Room: Bayside room 5 & 6	Room: Level 17
	Symposium 3: **Inflammation and immunity: New frontiers for the treatment of cardiovascular and neurological diseases**	**Symposium 4:** **Addressing the complexities of Cytochrome P450 metabolism**	**Symposium 5:** **Drug discovery: a collaborative effort**
	Chair: Dr Tracey Gaspari	**Chair**: Dr Andrew Rowland	**Chair**: Dr Angela Finch
	Role of inflammation in Neuropsychiatric disorders - 202 Prof Bernhard Baune, University of Adelaide	**The importance of basic drug metabolism research to the Pharmaceutical Industry: Success in the past 30 years and needs for the future - 206** Prof Fred Guengerich, Vanderbilt University, USA	**Influenza drugs – more than an effective drug is needed for success - 209** Dr Jennifer McKimm-Breschkin, CSIRO Materials Science and Engineering
	B Cell Subtypes in Atherosclerosis. Therapeutic Implications - 203 Prof Alex Bobik, Baker IDI Heart and Diabetes Institute	**Innovative approaches for the assessment of pharmacokinetics and drug-drug interactions - 207** Prof Gerd Mikus, Heidelberg University, Germany	**The Discovery of Novel Anticancer Agents: The Industry-Academic interface - 210** Dr Christopher Burns, Chemical Biology Division, The Walter and Eliza Hall Institute of Medical Research
	Therapeutic targeting of the innate immune complement system in neurodegenerative disease - 204 Dr Trent Woodruff, School of Biomedical Sciences, The University of Queensland	**Substrate selectivities and structure-function relationships of human cytochrome P450 enzymes - 208** Prof John Miners, Pramod Nair, Clinical Pharmacology, Flinders University	**Experiences in collaborative Drug Discovery and Development - 211** Dr Alistair Draffan, Director, Drug Discovery, Biota
	Mineralocorticoid receptors, not just salt and water - 205 Dr Morag Young, Cardiovascular Endocrinology, Prince Henry's Institute	Sponsored by Flinders University University of South Australia Australian Centre for Pharmacometrics	**Drug development in a University setting - factors for success - 212** Prof William Denny, Auckland Cancer Society Research Centre, University of Auckland, New Zealand
12:30 – 14:00	Level 2 foyer	Room: The Pavillion	Room: Bourke room 1 & 2
	Lunch with exhibitors	**Poster presentations: Inflammation/ Respiratory; Neuro- and Behavioural Pharmacology; Pharmacogenomics; Toxicology; Urogenital and Gastrointestinal; Education** **ASCEPT Poster Prize presentations: TBA**	**SIG meeting: Drug Discovery**
			Room: Bayside room 5 & 6
			SIG meetings: Clinical Pharmacology



14:00 – 16:00	Room: Bourke room 1 & 2	Room: Bayside room 5 & 6	Room: Level 17
	Oral presentations 8: ASCEPT Garth McQueen Oral Prize	**Oral presentations 9: Clinical Pharmacology**	**Oral presentations 10: Cardiovascular 2**
	Chair: Dr Barbara Kemp-Harper	**Chair**: Prof Carl Kirkpatrick	**Chair**: Prof Emilio Badoer
	Functional analysis of novel bitter ligands in rodent and human cardiac tissue ex vivo - 213 Simon Foster, School of Biomedical Sciences, The University of Queensland	**Building bridges across the silos: Developing evidence-based guidance for intravenous paracetamol use in the paediatric population - 221** Madlen Gazarian, New South Wales Therapeutic Advisory Group (NSW TAG); The University of New South Wales	**The cardioprotective effects of stevia and verapamil in hypertensive rats - 229** Andrew Fenning, CQUniversity
	Membrane-dependent control of cardiac function, ischaemic tolerance and opioidergic protection - 214 Louise See Hoe, Griffith University	**Does worsening renal function lead to worse long term outcomes in RAAS inhibitor treated patients with left ventricular systolic dysfunction? A meta-analysis of 20,573 patients. - 222** Ingrid Hopper, CCRET, Monash University	**A CXC-motif receptor 2 (CXCR2) antagonist, SB225002, does not reduce renal fibrosis or systolic blood pressure in deoxycorticosterone-induced hypertension in mice - 230** Mark Francis, Department of Pharmacology, Monash University
	NOX2 oxidase deficiency promotes plaque stability in advanced atherosclerosis - 215 Michelle Bullen, Department of Pharmacology, Monash University	**Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: A meta-analysis of randomized clinical trials. - 223** Shiying Wu, CCRE Therapeutics, Monash University Medical School, Monash University	**Anti-inflammatory actions of annexin-A1 peptide Ac2-26 after myocardial reperfusion injury in mice *in vivo* - 231** Renming Li, Department of Pharmacology and Therapeutics, The University of Melbourne; Basic and Clinical Cardiology, Baker IDI Heart & Diabetes Institute
	A novel model using weight change to describe the disease progression of type 2 diabetes - 216 Steve Choy, Department of Pharmaceutical Biosciences, Uppsala University	**Assessment of medication use in Australian prospective longitudinal cohort studies: a missed opportunity - 224** Susan Poole, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University; Pharmacy Department, Alfred Health	**Prostacyclin signalling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis - 232** Hitesh Peshavariya, Centre for Eye Research Australia, The University of Melbourne; O'Brien Institute
	Unravelling the mechanism of TGF-ß-induced epithelial glucocorticoid resistance through Next-Generation Sequencing (RNA-seq) - 217 Christine Keenan, Department of Pharmacology and Therapeutics, The University of Melbourne	**Optimal sampling of antipsychotic medicines: A Pharmacometric approach - 225** Vidya Perera, Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research; Faculty of Pharmacy and Pharmaceutical Sciences, State University of New York; Department of Psychiatry, Western New York Veteran Affairs Hospital	**The concomitant coronary vasodilator and positive inotropic actions of Angeli's salt in the intact rat heart are mediated by nitroxyl and soluble guanylyl cyclase-dependent mechanisms - 233** Kai Yee Chin, Heart Failure Pharmacology, Baker IDI Heart & Diabetes Institute; School of Medical Science, Health Innovations Research Institute, RMIT University
	Altered protein expression with secretory pathway calcium ATPase 1 (SPCA1) silencing in MDA-MB-231 breast cancer cells - 218 Jane Lee, School of Pharmacy, The University of Queensland	**The performance of cystatin C- and creatinine-based eGFR equations for predicting gentamicin clearance - 226** Paul Chin, Department of Clinical Pharmacology, Christchurch Hospital; Department of Medicine, University of Otago	**Inflammatory cell composition in the brain associated with functional outcome following cerebral ischemia - 234** Stephanie Whittle, Monash University
	Targeting type-1 interferon signalling is neuroprotective in the MPTP mouse model of Parkinson's disease - 219 Bevan Main, Department of Pharmacology and Therapeutics, The University of Melbourne	**Patient perspectives' regarding long term warfarin therapy and potential transition to new oral anticoagulant therapy - 227** Elizabeth Gebler-Hughes, School of Medicine, Flinders University	**Signalling profiles and changes in gene expression produced by serelaxin in human vascular cells - 235** Mohsin Sarwar, Monash Institute of Pharmaceutical Sciences, Monash University
	Effect of ageing and paracetamol on the intrinsic death pathway in Fischer 344 rat livers - 220 John Mach, Laboratory of Ageing and Pharmacology, Kolling Institute of Medical Research; Department of Clinical Pharmacology and Aged Care, Royal North Shore Hospital; Sydney Medical School, The University of Sydney	**Development of indicators for quality use of medicines (QUM) in acute mental health care - 228** Alexandra Bennett, New South Wales Therapeutic Advisory Group	**A novel mechanism of beta2-adrenoceptor-stimulated biogenesis in skeletal muscle - 236** Jon Merlin, Drug Discovery Biology, MIPS, Monash University
16:00 – 16:30	Level 2 foyer		
	Afternoon tea with exhibitors		
16:30 – 17:30	Room: Level 17		
	Plenary presentation - Japanese Pharmacological Society Visitor		
	Chair: Prof David Le Couteur, ASCEPT President		
	Calcium regulation of cell functions: From basic principles to therapeutic targets - 237 Professor Masamitsu Iino, The University of Tokyo Bunkyo-ku, Japan		
17:30 – 18:30	Bayside rooms 5 & 6		
	ASCEPT Annual General Meeting		
19:30 – 22:30	Level 17		
	Conference dinner (pre-dinner drinks from 19:00)		

Wednesday 4 December, 2013

08:30 – 13:00	Registration desk open		
08:30 – 09:00	Room: Bourke room 1 & 2	Room: Bayside room 5 & 6	
	SIG meeting: Cardiovascular	**SIG meeting: Drug Disposition and Response**	
09:00 – 11:00	Room: Bourke room 1 & 2	Room: Bayside room 5 & 6	Room: Level 17
	Symposium 6: **Interstitial cells as novel pharmacological targets: advances in gastro-intestinal and urogenital systems**	**Symposium 7:** **From pipette to patient to policy – training pharmacologists for the future**	**Oral presentations 11:** **Drug Discovery 2**
	Chair: Prof Russ Chess-Williams	**Chair**: Dr Elizabeth Davis	**Chair**: Assoc Prof Peter Molenaar
	Do Interstitial cells regulate spontaneous activity in the prostate? - 301 Dr Betty Exintaris, Monash University	**Faculty-wide adoption of an active learning approach to replace didactic lectures - 305** Dr Paul White, Monash University	**Allosteric modulation of muscarinic acetylcholine receptor regulation - 308** Holly Yeatman, Drug Discovery Biology, MIPS, Monash University
	Interstitial cells in the gastrointestinal system: multifaceted coordinators of motility - 302 Dr Scott Smid, University of Adelaide	**Developing research competency - 306** Assoc Prof Renae Ryan, The University of Sydney	**Development of an irreversible allosteric ligand for the M1 muscarinic acetylcholine receptor - 309** Briana Davie, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences
	Interstitial cells in the bladder: role in ageing & pathology - 303 Dr Donna Sellers, Bond University	**Clinical pharmacology specialty training - 307** Assoc Prof Matt Doogue, Otago University	**A tyrosine kinase inhibitor blocks PAR2-mediated pain - 310** Megan Grace, Health and Innovations Research Institute, RMIT University
	hERG channel activity controls uterine contraction in labour and this fails in obesity - 304 Prof Helena Parkington, Monash University	**Discussion Panel: Does our current teaching adequately prepare graduates of pharmacology for their careers?** **Moderator**: Dr Anna Marie Babey, The University of New England **Panel**: Dr David Foster, University of South Australia; Ms Claire Johnston, The University of Sydney; Mr Adrian Campbell, The University of New South Wales; Emeritus Prof Graham Johnston AM, The University of Sydney	**A Structure-Activity Analysis of Biased Agonism at the Dopamine D2 Receptor - 311** Robert Lane, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences
			Brite adipocytes derived from subcutaneous white adipose tissue display enhanced β-adrenoceptor function - 312 Bronwyn Evans, Monash Institute Pharmaceutical Sciences, Monash University
			Orexin 2 receptor antagonism induces sleep: a novel series of Orexin receptor antagonists with distinct effects on sleep architecture - 313 Daniel Hoyer, Department of Pharmacology and Therapeutics, MDHS, The University of Melbourne; The Florey Institute of Pharmacology and Therapeutics
			Understanding the spatio-temporal profile of compartmentalised G protein coupled receptor signalling - 314 Michelle Halls, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University
			Anti-Proteus activity of some South African medicinal plants: their potential for the prevention of rheumatoid arthritis - 315 Ian Cock, Griffith University
11:00 – 11:30	Morning tea		
11:30 – 12:30	Room: Level 17		
	Panel discussion		
	Chair: Prof Dom Geraghty		
	Dr Patrick Smith, Chief Scientific Officer, d3 Medicine, USA Dr Craig Rayner, CEO, d3 Medicine Prof Fred Guengerich, Vanderbilt University, USA Prof William Denny, Auckland Cancer Society Research Centre, University of Auckland, New Zealand		
12:30 – 13:00	Room: Level 17		
	Awards and Conference close		
	Prof David Le Couteur, ASCEPT President Dr Barbara Kemp-Harper		

Poster presentations

Monday 2 December, 7.30am – 8.30am and 12.00pm – 1.30pm

Posterboard Number	Abstract title	Presenter	Paper reference	Session theme
401	Acute tocomin treatment improves endothelium-dependent relaxation in aortae from diabetic and western diet fed rats	Saher Ali	151	Cardiovascular
402	NOX2 oxidase deficiency promotes plaque stability in advanced atherosclerosis	Michelle Bullen	215	Cardiovascular
403	Omega-3 fatty acids modulate Weibel-Palade body degranulation and actin cytoskeleton rearrangement in PMA-stimulated human umbilical vein endothelial cells	Corinna Burgin-Maunder	403	Cardiovascular
404	The concomitant coronary vasodilator and positive inotropic actions of Angeli's salt in the intact rat heart are mediated by nitroxyl and soluble guanylyl cyclase-dependent mechanisms	Kai Yee Chin	233	Cardiovascular
405	Dissociation between proportion of perhexiline assays within therapeutic range and clinical demographics or steady-state pharmacokinetics during long-term therapy	Cher-Rin Chong	405	Cardiovascular
406	Lower dose statin pharmacotherapy may be sufficient and safer	Simon Dimmitt	406	Cardiovascular
407	The influence of the fibrotic microenvironment on glucocorticoid sensitivity in lung fibroblasts	Christos Dukas	407	Cardiovascular
408	Evidence for a role of NOX5 in macrophage pathobiology	David Firth	152	Cardiovascular
409	Taste GPCR functionality and contractile effects in human hearts	Simon Foster	409	Cardiovascular
410	Functional analysis of novel bitter ligands in rodent and human cardiac tissue ex vivo	Simon Foster	213	Cardiovascular
411	A CXC-motif receptor 2 (CXCR2) antagonist, SB225002, does not reduce renal fibrosis or systolic blood pressure in deoxycorticosterone-induced hypertension in mice	Mark Francis	230	Cardiovascular
412	TGFß-induced non-canonical pathway regulates Nox4 expression and proliferation of endothelial cells	Nora Hakami	412	Cardiovascular
413	Hydrogen sulfide as a vasorelaxant in mouse mesenteric arteries	Joanne Hart	413	Cardiovascular
414	Pharmacological inhibition or genetic deletion of the AT4 Receptor/IRAP provides protection against Ang II-mediated cardiac hypertrophy and cardiac fibrosis	Huey Wen Lee	157	Cardiovascular
415	Anti-inflammatory actions of annexin-A1 peptide Ac2-26 after myocardial reperfusion injury in mice *in vivo*	RENMING LI	231	Cardiovascular
416	Pharmacological inhibition of IL-1ß signalling in DOCA/salt-induced hypertension in mice does not reduce renal inflammation or blood pressure	Yeong Hann Ling	416	Cardiovascular
417	Effects of dantrolene sodium and azumolene on cardiac calcium activation and CYP450 metabolism	Christine Loescher	417	Cardiovascular
418	Endothelin causes vasoconstriction of rat cerebral arteries by differential activation of voltage-operated and non-voltage-operated calcium channels	Yohannes Mamo	418	Cardiovascular
419	A novel mechanism of beta2-adrenoceptor-stimulated biogenesis in skeletal muscle	Jon Merlin	236	Cardiovascular
420	Advanced glycation end-products (AGE), RAGE and ROS accumulation in rat isolated arteries	Tim Murphy	420	Cardiovascular
421	Evidence for reciprocal dysregulation of asymmetric dimethylarginine and myeloperoxidase in atrial fibrillation	Nathan Procter	421	Cardiovascular
422	The DPP-4 inhibitor linagliptan improves endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose and hyperglycaemia in STZ-induced diabetic rats	Owen Woodman	422	Cardiovascular
423	Signalling profiles and changes in gene expression produced by serelaxin in human vascular cells	Mohsin Sarwar	235	Cardiovascular
424	Membrane-dependent control of cardiac function, ischaemic tolerance and opioidergic protection	Louise See Hoe	214	Cardiovascular
425	Distinct roles for the two human platelet thrombin receptors, PAR1 and PAR4, in thrombus formation	Tejminder Sidhu	156	Cardiovascular
426	Impact of upregulated O-GlcNAcylation on left ventricular (LV) inotropic responsiveness in diabetic heart	Rochelle Sleaby	426	Cardiovascular
427	Development of a UPLC-MS based approach to quantify a panel of key arginine metabolites in human serum	Madele Van Dyk	427	Cardiovascular
428	Omega-3 fatty acids decrease ROS production in an apoE-/- mouse model of abdominal aortic dissection	Kathryn Wales	428	Cardiovascular
429	The epidermal growth factor receptor ErbB4 mediates neuregulin-induced, but not angiotensin II-induced, cardiomyocyte hypertrophy	Zhen Wang	158	Cardiovascular
430	Inflammatory cell composition in the brain associated with functional outcome following cerebral ischemia	Stephanie Whittle	234	Cardiovascular
445	Development and evaluation of microemulsion formulations for transdermal delivery of caffeine	Eman Abd	445	Clinical Pharmacology
446	Over-the-counter interventions and advice for acute low back pain: systematic review and meta-analysis	Christina Abdel Shaheed	446	Clinical Pharmacology
447	Estimating fat-free mass in children	Hesham Al-Sallami	447	Clinical Pharmacology
448	The inflammation-resolving trihydroxydocosahexaenoic acid derivative, resolvin D2, supports MCF-7 cell proliferation via activation of estrogen receptor	Nuha Al-Zaubai	448	Clinical Pharmacology
449	Dehydration and diuretic use are common in older patients presenting with falls, particularly amongst the frail	Alexander Bennett	449	Clinical Pharmacology
450	Prevalence of chemotherapy dose reductions in obese women with breast cancer	Matthew Cheng	450	Clinical Pharmacology
451	Understanding and improving aminoglycoside use	Natasha Diasinos	451	Clinical Pharmacology
452	The management of medicines in general practice by subjects with diabetes and high glycosylated haemoglobin levels	Sheila Doggrell	452	Clinical Pharmacology
453	Rethinking medicines decision-making in Australian hospitals: Guiding principles for the quality use of off-label medicines	Madlen Gazarian	453	Clinical Pharmacology
454	The effect of old age and frailty on intravenous fentanyl and midazolam pharmacodynamics	Luke Harb	454	Clinical Pharmacology
455	Understanding and improving allopurinol use in a tertiary hospital	Rachel Hmar	455	Clinical Pharmacology
456	Does worsening renal function lead to worse long term outcomes in RAAS inhibitor treated patients with left ventricular systolic dysfunction? A meta-analysis of 20,573 patients.	Ingrid Hopper	222	Clinical Pharmacology
457	Pharmacokinetic studies in old age and frailty: The utilization of population modeling	Claire Johnston	457	Clinical Pharmacology
458	Do plasma oxypurinol concentrations provide a better fit to theoretical relationships than allopurinol dose?	Diluk Kannangara	458	Clinical Pharmacology
459	Can we predict the optimum dose of allopurinol needed to effectively treat gout from any plasma urate?	Diluk Kannangara	459	Clinical Pharmacology
460	Anticholinergic load in community dwelling elderly Australians with dementia	Karen Kerr	460	Clinical Pharmacology

Posterboard Number	Abstract title	Presenter	Paper reference	Session theme
461	Changes in polypharmacy, hyperpolypharmacy and exposure to anticholinergic and sedative medicines: A five-year study of community-dwelling older men	Clara Leung	461	Clinical Pharmacology
462	Dose individualization of the CYP3A substrate simvastatin by a midazolam microdose CYP3A activity measurement	Gerd Mikus	462	Clinical Pharmacology
463	Understanding and improving metformin use in hospital	Ji-Woong Moon	463	Clinical Pharmacology
464	Over-the-counter analgesic use by community patients in the Northern Territory, Australia	Suong Ngo	464	Clinical Pharmacology
465	Garlic and skin cancer prevention - Preclinical perspectives	Suong Ngo	465	Clinical Pharmacology
466	Topical treatment with aspirin does not prevent non-melanoma skin cancer in mice	Suong Ngo	466	Clinical Pharmacology
467	Assessment of medication use in Australian prospective longitudinal cohort studies: a missed opportunity	Susan Poole	224	Clinical Pharmacology
468	Consortium for clarity in medicine labelling	Susan Tett, Gillian Shenfield	468	Clinical Pharmacology
469	Prevalence and factors associated with statin use in geriatric oncology	Justin Turner	469	Clinical Pharmacology
470	Factors associated with buprenorphine abuse among clients seeking treatment in Finland	Hanna Uosukainen	470	Clinical Pharmacology
471	Monitoring the anti-Helicobacter Pylori activity of some nutritional antibiotics *in vivo*, using the MetAtron/Hunter	Michael Whitehouse	471	Clinical Pharmacology
472	Polypharmacy and medication regimen complexity as predictors of hospital discharge directly to home: a cohort study	Barbara Wimmer	472	Clinical Pharmacology
473	The influence of CYP2C9 and VKORC1 genotype on the predictive performance of a Bayesian forecasting method for warfarin therapy	Dan Wright	473	Clinical Pharmacology
474	Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: A meta-analysis of randomized clinical trials.	Shiying Wu	223	Clinical Pharmacology
477	Bioequivalence of generic mycophenolate mofetil in paediatric renal transplantation	David Metz	135	Clinical Pharmacology Trainee
478	SimCYP assessment of population level inter-individual variability in olanzapine clearance	Andrew Rowland	478	Clinical Pharmacology Trainee
479	Metformin in haemodialysis patients with diabetes: short term safety and glycaemic effects	Tilenka Thynne	479	Clinical Pharmacology Trainee
494	Molecular Determinants of Allosteric Ligand Binding and Modulation at the M1 Muscarinic Acetylcholine Receptor.	Alaa Abdul-Ridha	122	Drug Discovery
495	Role of reactive oxygen species in calcium signalling in hypoxia-induced epithelial-mesenchymal transition	Iman Azimi	495	Drug Discovery
496	Biased agonism at the adenosine A1 receptor: Implications for cytoprotection.	Jo-Anne Baltos	496	Drug Discovery
497	Novel benzamide derivatives as potent P2X7 receptor antagonists	Melissa Barron	497	Drug Discovery
498	Identifying origins of affinity, selectivity and allosterism on the α1 adrenoceptors	Adrian Campbell	126	Drug Discovery
499	Trapped in the act: The α4-α4 interface is an additional binding site for antagonists that can differentiate between stoichiometries of α4ß2 nAChRs	Mary Chebib	499	Drug Discovery
500	Biochemical and functional characterisation of a ß2-adrenoceptor multi-protein complex (signalosome)	Srgjan Civciristov	500	Drug Discovery
502	PAR2-dependent opening of TRPV4 does not depend on PLC activation and Calcium release from stores	William Darby	502	Drug Discovery
503	Synthesis and pharmacological evaluation of irreversible allosteric ligands for the M1 muscarinic acetylcholine receptor	Briana Davie	309	Drug Discovery
504	Identification of receptor-ligand interactions of a novel bitopic ligand at the dopamine D2 receptor	Chris Draper-Joyce	504	Drug Discovery
505	The potential of quinazolines as CYP450 inhibitors and cardiac modulators	Ben Farrar	505	Drug Discovery
506	TRPV1 expression in haematological malignancies	Dom Geraghty	506	Drug Discovery
507	From structure to function: understanding the role of a highly conserved intramembranous binding pocket at GPCRs.	Adrienne Grech	507	Drug Discovery
508	Expression of known and novel androgen receptor splice variants in human tissues and breast cancer cells	Dong Gui Hu	508	Drug Discovery
509	A novel, high affinity binding site in α9α10 nicotinic acetylcholine receptor	Dinesh C. Indurthi	509	Drug Discovery
510	In vitro screening of novel P2X7 receptor antagonists with potential antidepressant activity	Alexander Jackson	510	Drug Discovery
511	Altered trafficking profiles of angiotensin II receptor heteromers	Elizabeth Johnstone	511	Drug Discovery
512	Pathway-selective modulation of CB1 receptor signalling by the allosteric modulator Org27569	Elham Khajehali	120	Drug Discovery
513	A structure-activity analysis of biased agonism at the dopamine D2 receptor	Carmen Klein Herenbrink	513	Drug Discovery
514	Probing the binding of allosteric modulators at the human calcium sensing receptor (CaSR)	Katie Leach	514	Drug Discovery
515	Altered protein expression with secretory pathway calcium ATPase 1 (SPCA1) silencing in MDA-MB-231 breast cancer cells	Jane Lee	218	Drug Discovery
516	The Synthesis and Biological Study of Curcumin Analogues as Anticancer Agents	Vivian Liao	516	Drug Discovery
517	Design and testing of novel anti-cancer agents targeting secretory pathway calcium ATPase	Jennifer Hsuan-Yu Lin	517	Drug Discovery
518	A switched on receptor - constitutive activity of the adenosine A2B receptor	Elizabeth McBrearty	518	Drug Discovery
519	Evaluation of the biological activity of novel trishomocubanes compounds at sigma receptor binding sites	Miral Mikhail	519	Drug Discovery
520	Structure-function analysis of allosteric ligand binding at the adenosine A1 receptor	Anh Thi Ngoc Nguyen	520	Drug Discovery
521	Calcium transporters and modulator profiling in trastuzumab-resistant SKBR3R breast cancer cells	Elena Pera	521	Drug Discovery
522	Activation of over-expressed calcium channels as a potential therapeutic strategy for the treatment for breast cancer	Amelia Peters	522	Drug Discovery
523	A flavonoid rich extract from Carpobrotus rossii protects against glucose intolerance	Adam Pirie	523	Drug Discovery
524	Elucidating the pharmacological signalling pathways underlying beta-adrenoceptor regulation of breast cancer metastasis	Cindy Pon	524	Drug Discovery
525	Serum-Induced SIRT1 Expression and Longevity in Older Men	Shajjia Razi	525	Drug Discovery
526	Investigating recruitment of regulatory proteins to the GLP-1R and their role in downstream signaling	Emilia Savage	526	Drug Discovery
527	Evaluation of the potential of Syzygium australe and Syzygium leuhmannii fruit extracts as antibacterial agents	Joseph Sirdaarta	527	Drug Discovery
528	Antimicrobial and anticancer activities of fruit extracts of the southern African medicinal plant Kigelia africana (sausage tree)	Joseph Sirdaarta	528	Drug Discovery
529	Wound healing from the outback: novel wound healing therapeutics from native Australian plants	Annnette Spierings	529	Drug Discovery
530	A targeted siRNA based screen to identify calcium transporters involved in the calcium-dependent regulation of ABCC3 gene expression in a model of breast cancer epithelial-mesenchymal transition (EMT)	Teneale Stewart	530	Drug Discovery
531	Biased signalling of endogenous opioids at the Mu receptor	Georgina Thompson	531	Drug Discovery
532	Teaching 'old' polymyxins new tricks: Next generation lipopeptides targeting Gram-negative 'superbugs'	Tony Velkov	532	Drug Discovery



Posterboard Number	Abstract title	Presenter	Paper reference	Session theme
533	Pyrazolopyrimidine derivatives as translocator protein ligands with potential anti-glioblastoma properties	Eryn Werry	533	Drug Discovery
534	Identification of calcium channels and pumps as therapeutic targets in breast cancer cells	Kunsala Yapa	534	Drug Discovery
552	Regulation by Rapamycin and NrF2 of the Expression Bile Acid Transporters in Liver Cells	Farhana Afroz	552	Drug Disposition and Response
553	Oxidative metabolism of rosiglitazone in the maternal and fetal sheep and human liver microsomes	Maryam Bazargan	553	Drug Disposition and Response
554	The Putative transmembrane domain 6 of the human Organic anion transporting polypeptide 1A2 (OATP1A2) determines transporter function via substrate recognition and protein quality control	Ting Chan	554	Drug Disposition and Response
555	Transcriptional up-regulation of human UDP-glucuronosyltransferase (UGT) 2B15 and 2B17 by tamoxifen and its active metabolite 4-hydroxyl-tamoxifen in breast cancer cells	Apichaya Chanawong	555	Drug Disposition and Response
556	Development of a novel HAMIN® topical local anaesthetic system for venepuncture	Zamri Chik	556	Drug Disposition and Response
557	Differences in CYP1A2 mediated 7-ethoxyresorufin (ERES) O-deethylation between heterologous expression systems	Alyce Dimmock	557	Drug Disposition and Response
558	Terbinafine in combination for the treatment of resistant or refractory mycoses: Investigating optimal dosing regimens using a physiologically-based pharmacokinetic model	Michael Dolton	558	Drug Disposition and Response
559	The effect of broccoli consumption on the activity of drug-metabolising enzymes in Europeans and South Asians: Study protocol	Shane Eagles	559	Drug Disposition and Response
560	The role of CYP3A4 and CYP2C19 in the human liver biotransformation of the dipeptidyl boronic acid bortezomib	Nuala Helsby	560	Drug Disposition and Response
561	In vitro assessment of metabolic drug-drug interactions potentially affecting olanzapine clearance	Saira Khan	561	Drug Disposition and Response
562	Imatinib PKPD relationship – Results from an ongoing study	Shaun Kumar	562	Drug Disposition and Response
563	*In vivo* biodistribution of water-dispersible CdTe/CdS quantum dots after intravenous and subcutaneous injection	Xiaowen Liang	563	Drug Disposition and Response
564	The effect of the traditional Chinese Medicine Bu Zhong Yi Qi Tang on drug metabolising enzyme activity in healthy volunteers: Study protocol	Bei-Lun Lin	564	Drug Disposition and Response
565	Comparison of hepatic disposition of quantum dots and organic dyes in rat using multiphoton microscope	Xin Liu	565	Drug Disposition and Response
566	Lipid conjugation for drug targetting	Quynh Mai	148	Drug Disposition and Response
567	Development and validation of an LC-MS/MS method for the quantification of the immunosuppressant, mycophenolic acid in human kidney transplant biopsies	Zaipul Md Dom	567	Drug Disposition and Response
568	Characterization of INS-1 832/3 cell line as a model system for studying GLP-1R regulation in diabetes	Kavita Pabreja	568	Drug Disposition and Response
569	Population pharmacokinetics of single-dose primaquine in Papua New Guinean children	Sam Salman	569	Drug Disposition and Response
570	Regulation of UDP glucuronosyltransferases 2B15 and 2B17 by microRNAs in cancer cell lines	Dhilushi Wijayakumara	143	Drug Disposition and Response
571	Delivery of anti-inflammation peptides from polyurethane films	Jing Zhang	571	Drug Disposition and Response

Tuesday 3 December, 8.00am – 9.00am and 12.30pm – 2.00pm

Posterboard Number	Abstract title	Presenter	Paper reference	Session theme
432	Are α_1-adrenoceptor antagonists effective in directly regulating smooth muscle tone in the human prostate gland?	Basu Chakrabarty	432	Urogenital and Gastrointestinal
433	An aqueous-soluble polar bioactive is responsible for the inhibitory effect of stinging nettle leaf extract on the purinergic component of contractility in the rat prostate gland	Nicole Eise	112	Urogenital and Gastrointestinal
434	Characterisation of relaxatory transmitters in the porcine internal anal sphincter	Russ Chess-Williams	434	Urogenital and Gastrointestinal
435	Characterisation of contractile responses to alpha1 adrenoceptor agonists in the porcine urethral circular smooth muscle	Donna Sellers	435	Urogenital and Gastrointestinal
436	Bile acids induce itch via a TGR5-TRPA1 dependent pathway	Gihan Jayaweera	436	Urogenital and Gastrointestinal
437	The effect of age on contractile responses of the porcine ureter to carbachol and phenylephrine	Iris Lim	437	Urogenital and Gastrointestinal
438	Effects of temperature and incubation times on cellular localization of Alpha1A-adrenoceptors labeled with BODIPY FL-prazosin (QAPB)	Linzi Lim	438	Urogenital and Gastrointestinal
439	The role of liver sinusoidal endothelial cells in the pathogenesis of insulin resistance	Mashani Mohamad	439	Urogenital and Gastrointestinal
440	Loss of Vitamin C synthesis worsens liver defenestration of the $Wrn^{\Delta hel/\Delta hel}$ mouse model-preliminary analysis	Natalie Ngu, Victoria Cogger, David Le Couteur	440	Urogenital and Gastrointestinal
441	α_{1a}-adrenoeptors stimulate glucose uptake via mTORC2, AMPK, and Rac1	Masaaki Sato	441	Urogenital and Gastrointestinal
442	The effect of sildenafil on spontaneous contractions in human prostate tissue	Brad Wittmer	111	Urogenital and Gastrointestinal
443	Characterisation of heteromeric 5-HT3 receptors: focusing on the 5-HT3C and 5-HT3E subunits	Nor Syafinaz Yaakob	443	Urogenital and Gastrointestinal
481	The subchronic phencyclidine rat: modelling the pathophysiology of schizophrenia and reversal with the antipsychotic, risperidone	Trisha Jenkins	481	Neuro-and Behavioural Pharmacology
482	The Direct Action of Cannabidiol at GABA-A Receptors	Timothy Bakas	482	Neuro- and Behavioural Pharmacology
483	Social and anxiety-like behaviours in mice with a genetic deletion of insulin regulated aminopeptidase	Joshua Bowditch	483	Neuro- and Behavioural Pharmacology
484	Expression of the small interacting protein CRIP1a modulates cannabinoid CB1 receptor mediated signalling	Nilushi Karunaratne	129	Neuro- and Behavioural Pharmacology
485	Ketamine and its metabolite inhibit lipopolysaccharide (LPS)-induced interleukin-6 production in a time- and concentration-dependent manner: potential involvement of multiple pathways	Yibai Li	485	Neuro- and Behavioural Pharmacology
486	Targeting type-1 interferon signalling is neuroprotective in the MPTP mouse model of Parkinson's disease	Bevan Main	219	Neuro- and Behavioural Pharmacology
487	The effect of quetiapine (Seroquel™) on conditioned place preference and elevated plus maze tests in rats when administered alone and in combination with (+)-amphetamine	Angela McLelland	487	Neuro- and Behavioural Pharmacology
488	Co-administration of the phytocannabinoid CBD modulates the neurobehavioural effects of acute and repeated THC exposure in mice	Stephanie Todd	488	Neuro- and Behavioural Pharmacology
489	Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics	Daniel Barratt	489	Pharmacogenomics
490	Does a transport defect underlie abnormal pharmacokinetics for the majority of 5-fluorouracil toxicity cases?	John Duley	490	Pharmacogenomics
491	Selected polymorphisms in the CLPTM1L gene are associated with lung cancer risk in Han Chinese population	Johnson Liu	491	Pharmacogenomics
493	Synergistic Regulation of UDP-Glucuronosyltransferase (UGT) 1A8, -1A9 and -1A10 Gene Expression by Caudal-Related Homeodomain Protein 2 (Cdx2) and the Hepatocyte Nuclear Factor 4α (HNF4α)	Siti N Mubarokah	493	Pharmacogenomics
536	Engaging and enhancing metabolism student learning capacity without compromising content or assessment standards	Ian Cock	536	Education
537	Prevalence of, and positive / negative issues surrounding, the use of e-learning tools	Janet Coller	537	Education
538	Development and implementation of a multi-disciplinary ethics broadening unit	Lynette Fernandes	538	Education
539	The impact of a multi-disciplinary ethics unit on student ethical perceptions	Lynette Fernandes	539	Education
540	Why dont students attend lectures?	Tina Hinton	540	Education
541	Operation of drug lists in Schools of Pharmacy	Julia Kennedy	541	Education
542	Developing a blended approach to the teaching of neuromuscular pharmacology and toxinology	Chau Khuong	542	Education
543	Assessment of pharmacists' knowledge and application of pharmacologic risk assessment tools in older people using a continuing professional development education method	Lisa Kouladjian	543	Education



Posterboard Number	Abstract title	Presenter	Paper reference	Session theme
544	Developing a clinical pharmacology (CP) training position in Perth, Western Australia	Poh Loh	544	Education
545	Acrolein relaxes mouse isolated tracheal smooth muscle via a TRPA1-dependent mechanism	Esther Cheah	545	Toxicology
547	Macronutrient related hepatotoxic changes provide a link between caloric restriction and inflamm-ageing	Rahul Gokarn	134	Toxicology
548	Effect of ageing and paracetamol on the intrinsic death pathway in Fischer 344 rat livers	John Mach	220	Toxicology
549	Cytochrome P450 2A5 a mitochondrial bilirubin oxidase?	Siti Nur Fadzilah Muhsain	549	Toxicology
550	Evaluation of in vitro assays as alternative strategies in predicting skin sensitisers	Chin Lin Wong	550	Toxicology
575	Sub-chronic smoking alters calcium signalling to increase small airway contraction in mice	Chantal Donovan	117	Inflammation/ respiratory
576	Visualisation of endothelin-1-mediated contraction of rat airways and arteries and mouse airways in situ using lung slices	Meaghan FitzPatrick	576	Inflammation/ respiratory
577	Bioactivity-guided fractionation of Australian native stingless bee (Tetragonula carbonaria) propolis extracts, based on in vitro free radical-scavenging and 5-lipoxygenase activities	Karina Hamilton	577	Inflammation/ respiratory
578	Evidence for endosomal reactive oxygen species production in endothelial cells in response to influenza A virus infection	Keshia Hendricks	116	Inflammation/ respiratory
579	Investigating the role of Nox2 oxidase and toll-like receptor 7 (TLR7) in influenza a virus (IAV)-induced reactive oxygen species (ROS) and cytokine expression in macrophages	Eunice To	579	Inflammation/ respiratory
580	Reduced number of mitochondria in NRF2 and NQO1 Knock-out mice	Alessandra Warren	580	Inflammation/ respiratory
581	Respiratory syncytial virus induces glucocorticoid-insensitivity in airway epithelial cells	Yuxiu Connie Xia	581	Inflammation/ respiratory